effect overlay
activetrials
Multiple Sclerosis

A phase III multicenter, randomized,double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with ocrelizumab in adult patients with primary  progressive multiple sclerosis
 

HREC: 2020.082
Principal Investigator: Dr Mark Marriott
Coordinator contact: Katherine Fazzolari
Funding: Commercial

SARS-CoV2 antibody-seroprevalence in patients with multiple sclerosis
 

HREC: 2020.305
Principal Investigator: Dr Chris Dwyer
Coordinator contact:
Funding: Non-Commercial
Multiple Sclerosis

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
 

HREC: 2022.014
Principal Investigator: Dr Ai-Lan Nguyen
Coordinator contact: Hasini Fernando
Funding: Non-Commercial
Multiple Sclerosis

B-cell repopulation in patients with multiple sclerosis treated with anti-CD20 therapies
 

HREC: 2023.079
Principal Investigator: Prof Tomas Kalincik
Coordinator contact:
Funding: Non-Commercial
Multiple Sclerosis

Prevalence and incidence study of neuromyelitis optica in Australia and New Zealand with population based sensitivity and specificity of NMO IgG antibody positivity
 

HREC: 2010.278
Principal Investigator: Dr Mark Marriott
Coordinator contact:
Funding: Non-Commercial